Company becomes sole first applicant for 45 mg strength, positioning itself for potential 180-day generic exclusivity in the US market
The newly approved treatment, SKINVIVE by JUVÉDERM, is now the first and only hyaluronic acid injectable cleared specifically for improving neck appearance
Company introduces bioequivalent version of Edarbi for hypertension treatment following U.S. FDA approval; product recorded annual U.S. sales of USD 53.5 million
Collaboration integrates MERCURIUS DRUG-seq technologies with Revvity’s screening portfolio, enabling scalable transcriptomic profiling for next-generation drug discovery and AI-driven research
New Shoolagiri plant strengthens Maiva’s global CDMO capabilities with advanced isolator technology, flexible production lines, and expanded capacity for complex injectable therapies
The milestone, announced from Wilmington, Delaware, is powered through additional Renewable Energy Certificates (RECs) and backed by US-sourced renewable generation
First installation of AI-powered AMULET SOPHINITY at NM Medical aims to strengthen early breast cancer detection
The newly commissioned facility strengthens the ’company’s capabilities in the development and manufacturing of generic and complex sterile injectable products
The approved product is therapeutically equivalent to Haldol tablets of Ortho McNeil Pharmaceutical
Ranluspec is the only interchangeable ranibizumab biosimilar approved in the United States in both vial and pre-filled syringe (PFS) presentations
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
